EUVIMEDEUVIMED entdecken
Crossref

Efficacy of molnupiravir and interferon for the treatment of SARS‐CoV‐2 in golden Syrian hamster

Danlei Liu iD, Ka-Yi Leung, Ruiqi Zhang, Hoi-Yan Lam, Yujing Fan, Xiaochun Xie, Kwok-Hung Chan, Ivan Fan-Ngai Hung

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Danlei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Antiviral Agents, Mesocricetus, COVID-19 Drug Treatment, Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Health and Medical Research Fund (HMRF) Commissioned Research on COVID-19 (Grant No.: COVID1903010).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mortality and hospitalization rate by COVID‐19 dropped significantly currently, but its seasonal outbreaks make antiviral treatment still vital. The mortality and hospitazation rate by COVID‐19 dropped significantly currently, but its seasonal ourbreaks make antiviral treatment still vital. In our study, syrian golden hamsters were treated with molnupiravir and interferons (IFNs) after SARS‐CoV‐2 infection. Their weight changes, pathological changes, virus replication and inflammation levels were evaluated. In the IFNs single treatment, only IFN‐α group reduced viral load ( p < 0.05) and virus titer in hamster lungs. The TNF‐α expression decreased significantly in both IFNs treatment at 2dpi. Histological and immunofluorescence results showed lung damage in the IFNs groups were milder at 4dpi. In the molnupiravir/IFN‐α combination treatment, weight loss and virus replication in lung were significantly decreased in the mono‐molnupiravir group and combination group ( p < 0.05), the expression of IL‐6, TNF‐α, IL‐1β and MIP‐1α also decreased significantly ( p < 0.05), but the combination treatment was not more effective than the mono‐molnupiravir treatment. Histological and immunofluorescence results showed the lung damage and inflammation in mono‐molnupiravir and combination groups were milder. In summary, IFNs treatment had anti‐inflammatory effect against SARS‐CoV‐2, only IFN‐α showed a weak antiviral effect. Molnupiravir/IFN‐α combination treatment was effective against SARS‐CoV‐2 but was not superior to mono‐molnupiravir treatment. IFN‐α could be considered for immunocompromised patients to stimulate and activate early immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsMesocricetusCOVID-19 Drug TreatmentLungVirus ReplicationSARS-CoV-2Viral LoadHydroxylaminesAnimalsCricetinaeDisease Models, AnimalCOVID-19CytidineDrug Therapy, CombinationInterferon-alphaCytokinesInterferonsMaleLeucine

Stichwörter der Autor:innen

SARS‐CoV‐2antiviralhamsterinterferonmolnupiravir

Substanzen

Antiviral AgentsmolnupiravirHydroxylaminesCytidineInterferon-alphaCytokinesInterferonsLeucine

Autor:innen und Institutionen

  • Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Department of Microbiology, Li Ka Shing faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • State Key Laboratory for Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Carol Yu Centre for Infection, Li Ka Shing faculty of Medicine, University of Hong Kong, Hong Kong, China.

ORCID-Profile: Danlei Liu

Förderung

  • Health and Medical Research Fund (HMRF) Commissioned Research on COVID-19 (Grant No.: COVID1903010)

Zitieren

APA

Liu, D., Leung, K. Y., Zhang, R., Lam, H. Y., Fan, Y., Xie, X., Chan, K. H., & Hung, I. F. (2024). Efficacy of molnupiravir and interferon for the treatment of SARS‐CoV‐2 in golden Syrian hamster. Journal of Medical Virology. https://doi.org/10.1002/jmv.29901

Vancouver

Liu D, Leung KY, Zhang R, Lam HY, Fan Y, Xie X, et al. Efficacy of molnupiravir and interferon for the treatment of SARS‐CoV‐2 in golden Syrian hamster. Journal of Medical Virology. 2024. doi:10.1002/jmv.29901

BibTeX
@article{Liu2024,
  author = {Liu, Danlei and Leung, Ka-Yi and Zhang, Ruiqi and Lam, Hoi-Yan and Fan, Yujing and Xie, Xiaochun and Chan, Kwok-Hung and Hung, Ivan Fan-Ngai},
  title = {Efficacy of molnupiravir and interferon for the treatment of SARS‐CoV‐2 in golden Syrian hamster},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29901}
}
Kostenlos starten →